Tetra Bio-Pharma Responds to Shareholders
December 04 2018 - 12:36PM
Tetra Bio-Pharma Inc (“
Tetra” or
“
TBP”), (TSX VENTURE: TBP) (OTCQB: TBPMF) -
Recent news regarding Aphria Inc. does not in any way affect
Tetra’s business, operations, clinical and drug registration and
source of supply. We are well funded to continue these activities
in 2019 with plans to expand our clinical activities in the U.S. We
remind shareholders that we are not a cannabis company but a
bio-pharmaceutical firm.
“It’s important for our shareholders to
understand that Tetra is not a cannabis company. We do not grow, or
sell cannabis,” said Dr. Guy Chamberland, CEO and CSO of Tetra
Bio-Pharma. “Like the internationally recognized GW Pharma, we are
a pharmaceutical company that discovers and develops prescription
drugs. This strategy is entirely different from the hundreds of
licensed producers and it is what makes Tetra completely unique.
Our business model has, and will continue to be, to take a
pharmaceutical pathway so that cannabinoid-derived drugs are
integrated into the regulated healthcare system.”
Tetra Bio-Pharma has made tremendous progress in
developing its lead products as prescription drugs and is in a
strong financial position to execute on our innovative and robust
business strategy. The following are some of the major achievements
that have taken place this year and that reflect Tetra’s work as a
bio-pharmaceutical innovator:
- Obtained the Drug Establishment
License for the manufacturing of PPP001;
- Completed the Type B and C meetings
with the U.S. FDA;
- Made a bid to acquire Panag Pharma
Inc. and grow its intellectual property;
- Advanced the timing of its filing
for PPP001 in Europe;
- Signed two distribution and sales
agreements with pharmaceutical companies based in Israel and
Portugal for our PPP001 drug product;
- Successfully setup a growing Hemp Energy Drink business and
shortly after ordered 1.7 million cans for sales;
- Hired senior pharmaceutical industry talent with depth of
experience to oversee operations in a timely, systematic way;
and
- Implemented plans to ensure supply of cannabis raw materials
thus avoiding back orders on drug or commercial
products.
Dr. Chamberland further stated, “Tetra has never
been in a stronger position in its history and looks forward to
continued execution of its strategy.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB:
TBPMF) is a biopharmaceutical leader in cannabinoid-based drug
discovery and development with a Health Canada approved,
and FDA reviewed, clinical program aimed at bringing
novel prescription drugs and treatments to patients and their
healthcare providers. The Company has several subsidiaries engaged
in the development of an advanced and growing pipeline of Bio
Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With
patients at the core of what we do, Tetra Bio-Pharma is
focused on providing rigorous scientific validation and safety data
required for inclusion into the existing bio pharma industry by
regulators, physicians and insurance companies.
For more information
visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-looking statementsSome
statements in this release may contain forward-looking information.
All statements, other than of historical fact, that address
activities, events or developments that the Company believes,
expects or anticipates will or may occur in the future (including,
without limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by use of the words "may",
"will", "should", "continue", "expect", "anticipate", "estimate",
"believe", "intend", "plan" or "project" or the negative of these
words or other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the ability to
obtain orphan drug status, the applicability of the discoveries
made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. While no definitive documentation has yet been signed
by the parties and there is no certainty that such documentation
will be signed. The forward-looking statements included in this
news release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
For further information, please contact
Tetra Bio-Pharma Inc.Robert (Bob) Bechard Executive Vice
President, Corporate Development and Licensing 514-817-2514
Investors@tetrabiopharma.com
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Sep 2023 to Sep 2024